Concepedia

Akram Alwithenani

AA

Statistics

Publications

3

Citations

52

H-Index

3

Active since

2021

Affiliations

Ottawa Hospital(Current)

University of Ottawa

Ottawa Hospital Research Institute

Akram Alwithenani is an author at Ottawa Hospital specializing in molecular oncology, medicine, and oncology.

Publications per year

2021–2024

3

Publications

3

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy

Boaz Wong, Anabel Bergeron, Glib Maznyi et al. · Molecular Therapy · 2023 · 23 citations · Full text

, , +17

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR

Akram Alwithenani, Drew Bethune, Mathieu Castonguay et al. · PLoS ONE · 2021 · 15 citations · Full text

, , +17

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy

Zaid Taha, Mathieu J. F. Crupi, Nouf Alluqmani et al. · Nature Communications · 2024 · 14 citations · Full text

, , +17

1–3 of 3